Latest news

Debiopharm and Genome & Company Join Forces to Create New Highly Specific Therapies For Cancer Patients

Le Challenge 2020 pour la qualité de vie du patient récompense le projet Oculus de sonnette connectée actionnée par le…

Phase II Research Against Covid-19 Launched in France with Debiopharm’s Antiviral Alisporivir

Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform

Debiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award

Debiopharm Launches Trilynx – A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head &…

Debiopharm Honored as a 2020 Swiss Biotech Success Story Winner for Outstanding Achievements over 40 Years

5e Challenge pour la Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress